{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36482293",
  "DateCompleted": {
    "Year": "2022",
    "Month": "12",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "01",
    "Day": "24"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "12",
        "Day": "08"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "209",
      "10.1186/s12985-022-01945-5"
    ],
    "Journal": {
      "ISSN": "1743-422X",
      "JournalIssue": {
        "Volume": "19",
        "Issue": "1",
        "PubDate": {
          "Year": "2022",
          "Month": "Dec",
          "Day": "08"
        }
      },
      "Title": "Virology journal",
      "ISOAbbreviation": "Virol J"
    },
    "ArticleTitle": "Discovery of vaccine-like recombinant SARS-CoV-2 circulating in human.",
    "Pagination": {
      "StartPage": "209",
      "MedlinePgn": "209"
    },
    "Abstract": {
      "AbstractText": [
        "For viral diseases, vaccination with live attenuated vaccine (LAV) is one of the most effective means for fighting the diseases. However, LAV occasionally overflows from vaccinated individuals circulate in the population with unforeseen consequences. Currently, SARS-CoV-2 LAVs are undergoing clinical trials. In this study, we found that the viruses isolated from Indian SARS CoV-2 infected persons may be candidate LAV-derived strains, indicating the risk of SARS-CoV-2 LAV spillover from vaccinated persons, increasing the complexity of SARS-CoV-2 detection. In addition, the property of frequent recombination of SARS-CoV-2 increases the chance of LAV virulence reversion. Therefore, how to distinguish the LAV viruses from the wild strain and how to avoid the recombination of the circulating vaccine strain and the wild strain are the challenges currently faced by SARS CoV-2 LAV development."
      ],
      "CopyrightInformation": "\u00a9 2022. The Author(s)."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "International Department, High School Attached to Shandong Normal University, Jinan, 250014, China."
          }
        ],
        "LastName": "He",
        "ForeName": "Daniel Chang",
        "Initials": "DC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Dongying Institute, Shandong Normal University, Dongying, 257000, China. hchqiang@sdnu.edu.cn."
          },
          {
            "Identifier": [],
            "Affiliation": "Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Science, Shandong Normal University, Jinan, 250014, Shandong Province, China. hchqiang@sdnu.edu.cn."
          }
        ],
        "LastName": "He",
        "ForeName": "Cheng-Qiang",
        "Initials": "CQ"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Virol J",
    "NlmUniqueID": "101231645",
    "ISSNLinking": "1743-422X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vaccines"
    }
  ],
  "CoiStatement": "The authors declare that they have no competing interests."
}